| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
GRAIL, Inc.$72
-3.04 (-4.01%)
F 15Pipeline Score MedTech · Commercial
Market Cap
2.88 B
EPS
-10.38
P/E Ratio
-
Value Trade
47.67 M
SEC Financials
Q1 2026Dilution Risk
Revenue
40.78 M
R&D Expenses
48.02 M
Operating CF
-86.99 M
Total Assets
2.80 B
Total Liabilities
302.79 M
Equity
2.50 B
D/E Ratio
12,345
11.98 %
Week
28.64 %
1 Month
35.3 %
3 Month
-22.01 %
6 Month
381.65 %
5 Year
381.65 %
All Time
Cash Data
Cash Position
889.66 M
Monthly Burn
29.00 M
Runway
28.8 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
509.99 K
52 Week Range
29.95 - 118.84
% held by Insiders
8.44 %
% held by Institutions
82.47 %
Enterprise Value
2.11 B
Total Shares
38.99 M
Short %
22.26 %
Float Shares
34.82 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F15
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 12%
Micro Cap (rank 803 of 911)
Percentile RankGRAIL, Inc. has significant pipeline risk (15/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Galleri | Multi-Cancer Early Detection | — | 2026-05-31 | 6.5-fold increase in cancer detection; 71% of newly detected cancers were in early stages I-III; 60% of diagnosed cancers were screen-detected (264/440); 60.3% positive predictive value (PPV) Read More | GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting Read More | |
Galleri | Multi-Cancer Early Detection | — | 2026-05-31 | 6.5-fold increase in cancer detection; 71% of newly detected cancers were in early stages I-III; 60% of diagnosed cancers were screen-detected (264/440); 60.3% positive predictive value (PPV) Read More | GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting Read More | |
Galleri | Multi-Cancer Early Detection | — | 2026-05-31 | 6.5-fold increase in cancer detection; 71% of newly detected cancers were in early stages I-III; 60% of diagnosed cancers were screen-detected (264/440); 60.3% positive predictive value (PPV) Read More | GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GRAL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GRAL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GRALGRAIL Completes $110 Million Equity Financing With Samsung Entities
GRAIL, Inc. has successfully closed a $110 million equity financing round with Samsung affiliates, which will aid in its mission to enhance early cancer detection. The investment will help GRAIL secure regulatory approvals and expand its Galleri test internationally, particularly in South Korea and potentially other Asian markets. This partnership is seen as a significant step towards improving cancer care through innovative screening technologies.
Read more →GRAL▲ +5.7%on this newsshared move
Welcome to the Superaging Era: Youth is no Longer the Holy Grail as Gen X and Millennials Chase the 100-Year Lifestyle
New research from Havas Health reveals a cultural shift in how society perceives aging, emphasizing vitality and quality of life over chronological age. The report, titled 'Superaging', highlights the emergence of a $33 trillion longevity economy, driven by proactive consumer attitudes towards aging. This shift is reshaping industries and consumer behavior, indicating a significant change in societal values regarding age.
Read more →GRALGRAIL, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 4, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
Bernstein Liebhard LLP is reminding investors of GRAIL, Inc. of the deadline to join a securities fraud class action lawsuit against the company. The lawsuit alleges that from May 13, 2025 to February 19, 2026, GRAIL made materially false statements that misled investors about its business operations and financial stability. As a result, investors who sold shares during this period might have suffered significant financial losses. The deadline to file as a lead plaintiff in the lawsuit is August 4, 2026.
Read more →GRALGRAIL LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against GRAIL, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against GRAIL, Inc. for allegedly providing misleading statements regarding its NHS Galleri trial results. The lawsuit claims that the trial's execution was inadequate in demonstrating a reduction in Stage III-IV cancers. Following the release of the trial results, which did not achieve the primary endpoint, GRAIL's stock price fell significantly, prompting investors to seek legal redress. Those affected have until August 4, 2026, to join the lawsuit and pursue their claims.
Read more →GRALGRAIL, INC. (GRAL) INVESTOR ALERT Investors With Large Losses in GRAIL, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
A shareholder has initiated a securities class action lawsuit against GRAIL, Inc. for allegedly misleading investors about the company's business operations and financial health. The lawsuit relates to shares purchased between May 13, 2025, and February 19, 2026. Investors are encouraged to act quickly if they wish to serve as lead plaintiff or to seek representation in the class action. Bernstein Liebhard LLP will represent the shareholders on a contingency fee basis, meaning no upfront fees are required.
Read more →GRAL▼ -10.2%on this news
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
GRAIL, Inc. announced positive results from its PATHFINDER 2 study, which involved 35,878 participants. The Galleri Multi-Cancer Early Detection Test demonstrated a 6.5-fold increase in cancer detection when combined with standard screenings for various cancers. Notably, 71% of the newly detected cancers were in early stages I-III, indicating the test's effectiveness in early diagnosis.
Read more →GRAL▼ -10.2%on this newsshared move
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
GRAIL, Inc. presented results from the NHS-Galleri trial at the 2026 ASCO Annual Meeting, highlighting the Galleri blood test's effectiveness in reducing Stage IV cancer diagnoses. The test demonstrated a 22% reduction in the second screening round and a 26% reduction in the third. Additionally, it increased the cancer detection rate significantly when used alongside standard care.
Read more →GRALGRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted...
GRAIL, Inc. recently announced the granting of equity awards, specifically restricted stock units (RSUs), to 56 new non-executive employees. This initiative is part of their Inducement Equity Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4). The RSUs, totaling 34,350 shares, will vest over four years, encouraging long-term employment. This move reflects GRAIL's commitment to expanding its workforce while focusing on its mission to detect cancer early.
Read more →GRALGRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
GRAIL, Inc. will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The presentation will focus on the company's mission to detect cancer early using advanced technologies. Live and replay webcasts will be available on GRAIL's investor relations website. The company aims to alleviate the global burden of cancer through innovative solutions.
Read more →GRALGRAIL to Present at the 2026 Jefferies Global Healthcare Conference
GRAIL, Inc. announced that its management will present at the 2026 Jefferies Global Healthcare Conference on June 3 at 7:35 a.m. ET. The company is dedicated to early cancer detection, utilizing advanced technologies to improve patient outcomes. The event will be accessible via live and archived webcasts on GRAIL's investor relations website.
Read more →GRAL▲ +15.3%on this news
GRAIL Reports First Quarter 2026 Financial Results
GRAIL, Inc. reported a strong financial performance for Q1 2026, with a 37% increase in Galleri revenue and a 50% rise in test volume. The company announced a partnership with Epic to integrate the Galleri test into their electronic health record platform, aiming to improve nationwide access. Despite these positive developments, GRAIL reported a significant net loss of $93.2 million for the quarter.
Read more →GRAL▲ +9.6%on this newsshared move
GRAIL to Present at the BofA Securities 2026 Health Care Conference GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company...
GRAIL, Inc. has announced its presentation at the BofA Securities 2026 Health Care Conference scheduled for May 12 in Las Vegas. The company's management will discuss its mission of early cancer detection, a critical area that can significantly improve treatment outcomes. Investors can access live and replay webcasts of the presentation through GRAIL's investor relations website. This event will enhance GRAIL's presence within the healthcare community and among potential investors.
Read more →GRALGRAIL to Announce First Quarter 2026 Financial Results
GRAIL, Inc. announced it will release its financial results for the first quarter of 2026 on May 5, 2026. Following the release, a webcast and conference call will be held to discuss the results and business progress. GRAIL focuses on early cancer detection using advanced technologies.
Read more →GRALGRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both ...
GRAIL, Inc. will present new data from the NHS-Galleri trial and the PATHFINDER 2 study at the 2026 ASCO Annual Meeting. These presentations will focus on the Galleri multi-cancer early detection (MCED) test, which has involved over 174,000 participants. The NHS-Galleri trial is notable for being a randomized controlled study aimed at enhancing cancer detection rates within the NHS, while the PATHFINDER 2 study represents the largest MCED interventional study in North America. GRAIL aims to highlight Galleri's clinical utility and performance in detecting cancers early.
Read more →GRALGRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide
GRAIL, Inc. has announced a collaboration with Epic to integrate the Galleri multi-cancer early detection test into Epic's electronic health record platform. This integration aims to streamline the ordering process for healthcare providers and enhance patient access to test results. The initiative is expected to improve early cancer detection and overall patient care, with broad availability anticipated by the end of 2026.
Read more →GRALGRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor
GRAIL, Inc. announced the retirement of CEO Bob Ragusa effective June 1, 2026, with President Josh Ofman appointed as his successor. Ofman, who has been with GRAIL since 2019, is expected to lead the company in advancing multi-cancer early detection. Ragusa will remain on the Board until his retirement date and will serve in an advisory role until March 2027.
Read more →GRALGRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GRAIL, Inc. has announced the granting of equity awards in the form of restricted stock units to 20 new non-executive employees. This initiative aims to incentivize their acceptance of employment under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a four-year period, promoting long-term commitment to the company's mission of early cancer detection.
Read more →GRALGRAIL to Present at the TD Cowen 46th Annual Health Care Conference
GRAIL, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The company aims to detect cancer early using innovative technologies. The presentation will be accessible via live and archived webcasts on their investor relations website. GRAIL's mission focuses on alleviating the global burden of cancer.
Read more →GRALGRAIL Reports Fourth Quarter and Full Year 2025 Financial Results Sold More Than 185,000 Galleri Tests in 2025, Growing U.S. Galleri Revenue 26% Year-Over-Year to $136.8 Million Completed Galleri PMA Submission to FDA Sh
GRAIL, Inc. reported substantial growth in its financial results for 2025, with a 26% increase in U.S. Galleri revenue. The company sold over 185,000 Galleri tests and completed significant trials, including the NHS-Galleri trial. Despite these achievements, GRAIL faced a net loss of $408.4 million for the year. The PMA submission to the FDA for the Galleri test adds both opportunity and uncertainty moving forward.
Read more →GRALLandmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced topline results from...
GRAIL, Inc. announced topline results from the NHS-Galleri trial, which evaluated the Galleri test's performance in detecting cancer early. While the primary endpoint of reducing Stage IV cancer diagnoses was not achieved, the results indicated a substantial decrease in Stage IV diagnoses and an increase in the detection of earlier-stage cancers. The findings support the potential for the Galleri test to enhance early cancer detection, facilitating earlier interventions that may lead to better outcomes. Additional analyses are planned to further understand the data and to extend the trial's follow-up period.
Read more →GRALGRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results
GRAIL, Inc. will announce its financial results for Q4 and the full year 2025 on February 19, 2026. The announcement will be followed by a webcast and conference call at 2:00 p.m. PT. GRAIL aims to detect cancer early using advanced technologies and is committed to improving cancer care.
Read more →GRALA Historic Moment in the Fight Against Cancer
The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act has been signed into law, establishing a new Medicare benefit category for multi-cancer early detection (MCED) tests. This bipartisan effort aims to improve cancer detection rates, particularly for cancers lacking routine screenings. The law is expected to enhance patient outcomes by facilitating earlier diagnosis and treatment options.
Read more →GRALWhy Finding Cancers Before It’s Too Late Matters More Than Ever
The article emphasizes the critical importance of early cancer detection, particularly in preventing diagnoses at Stage IV, where treatment options are limited. It highlights the significant survival benefits associated with Stage III cancers and discusses the potential public health impact of reducing late-stage diagnoses. Emerging screening technologies, such as multi-cancer early detection tests, are positioned as key solutions to improve cancer outcomes.
Read more →GRALGRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
GRAIL, Inc. has submitted a Premarket Approval application to the FDA for its Galleri multi-cancer early detection test. This submission follows rigorous studies, including the PATHFINDER 2 study and the NHS-Galleri trial, aimed at demonstrating the test's effectiveness in reducing late-stage cancer diagnoses. The Galleri test is expected to improve cancer screening outcomes significantly.
Read more →GRALGRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference
GRAIL, Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2025. The presentation will focus on the company's mission to detect cancer early using innovative technologies. Webcasts of the event will be available for live viewing and later access. GRAIL aims to alleviate the global cancer burden through advanced detection methods.
Read more →GRAL▲ +8%on this news· ran to +37% by day 3
GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference
GRAIL, Inc. announced its participation in the Piper Sandler 37th Annual Healthcare Conference scheduled for December 2, 2025. The presentation will highlight the company's mission to detect cancer early using advanced technologies. Interested parties can access live and archived webcasts through GRAIL's investor relations website.
Read more →GRALGRAIL Reports Third Quarter 2025 Financial Results
GRAIL, Inc. reported its third quarter 2025 financial results, showcasing a 28% increase in U.S. Galleri revenue to $32.6 million and a 39% rise in Galleri tests sold. Despite a net loss of $89 million, the company maintains a strong cash position exceeding $850 million. GRAIL anticipates submitting a PMA to the FDA in the first quarter of 2026.
Read more →GRAL▼ -5.4%on this news
The NHS-Galleri trial: What to expect in 2026 from the world’s first randomized controlled trial of a Multi-Cancer Early Detection test, Galleri<sup>®</sup>
The NHS-Galleri trial, initiated in 2021, is the first randomized controlled trial for a Multi-Cancer Early Detection test, Galleri. It aims to assess whether annual screening can reduce late-stage cancer incidence. With over 140,000 participants enrolled, results are expected in 2026, potentially transforming cancer detection and treatment outcomes.
Read more →GRALGRAIL to Present at 7th Annual Wolfe Research Healthcare Conference
GRAIL, Inc. will present at the 7th Annual Wolfe Research Healthcare Conference on November 18, 2025. The company's mission focuses on early cancer detection using advanced technologies. The presentation will be accessible via live and replay webcasts on their investor relations website.
Read more →GRALGRAIL to Announce Third Quarter 2025 Financial Results GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue...
GRAIL, Inc. announced that it will release its financial results for the third quarter of 2025 on November 12, 2025, followed by a webcast to discuss the outcomes. The company will also hold an Analyst Day on November 13, 2025, at its central laboratories in Research Triangle Park, North Carolina. These events demonstrate GRAIL's commitment to engaging with stakeholders regarding its business progress and financial performance.
Read more →GRAL▲ +17.8%on this news
GRAIL, Inc. Announces $325.0 Million Private Placement Financing
GRAIL, Inc. has announced a private placement financing expected to yield approximately $325 million. The funding will support its commercial activities and working capital needs. The deal involves participation from various institutional investors and is anticipated to close on October 21, 2025. GRAIL aims to use these funds to further its mission of early cancer detection.
Read more →GRAL▲ +17.8%on this newsshared move
GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)
GRAIL and the University of Oxford will present positive long-term data from the SYMPLIFY study at the Early Detection of Cancer Conference. The study highlights that one-third of participants initially thought to have false positives were later diagnosed with cancer, with the Galleri test achieving an updated positive predictive value of 84.2%. These findings emphasize the importance of continued follow-up for accurate cancer detection in symptomatic individuals.
Read more →GRAL▲ +17.8%on this newsshared move
GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
GRAIL, Inc. announced positive results from its PATHFINDER 2 study, showcasing the Galleri multi-cancer early detection blood test. The study revealed a more than seven-fold increase in cancer detection when combined with recommended screenings. Notably, over half of the cancers detected were early-stage, and a significant portion lacked existing screening recommendations.
Read more →GRAL▲ +14.4%on this newsshared move
Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL's Galleri® Multi-Cancer Early Detection Test to Asia
Samsung C&T and Samsung Electronics have entered a strategic collaboration with GRAIL to commercialize the Galleri multi-cancer early detection test in South Korea, with potential expansion to Japan and Singapore. The partnership includes a $110 million equity investment into GRAIL, aimed at enhancing cancer screening capabilities in Asia. The collaboration is expected to drive adoption and integration of innovative technologies in healthcare.
Read more →GRALPATHFINDER 2: What to Expect from the Largest U.S. Multi-Cancer Early Detection (MCED) Interventional Trial
The PATHFINDER 2 trial is set to evaluate the Galleri multi-cancer early detection test, focusing on its performance and safety in a diverse population. Enrolling nearly 36,000 participants, the trial aims to assess the cancer detection rate alongside standard screening tests. Initial results are anticipated at the ESMO Congress in October 2025, marking a pivotal moment for MCED implementation in clinical settings.
Read more →GRALMaking Sense of the Numbers: Interpreting Multi-Cancer Early Detection Test Performance
The article discusses the performance metrics of multi-cancer early detection tests. It highlights the importance of interpreting these numbers accurately. The author, Megan P. Hall, emphasizes the need for clarity in understanding test results. The piece aims to provide insights into the complexities of cancer detection methodologies.
Read more →GRALGRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC
GRAIL, Inc. will present new data on its Galleri multi-cancer early detection test at the ESMO Congress 2025 and EDCC. The PATHFINDER 2 study results indicate improved cancer detection rates when Galleri is added to standard screening. Additionally, findings from the SYMPLIFY and REFLECTION studies will be showcased, emphasizing Galleri's performance in various populations.
Read more →GRAL▼ -5.6%on this news
GRAIL to Present at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company...
GRAIL, Inc. will present at the Bernstein Insights Healthcare Leaders and Disruptors forum on September 24. The event focuses on early detection of cancer, aligning with GRAIL's mission to enhance treatment outcomes. Live and recorded webcasts of the event will be available on the company's investor relations website for at least 30 days. This presentation is expected to showcase GRAIL's advancements in cancer detection.
Read more →GRALGRAIL to Present at Morgan Stanley 23rd Annual Global Healthcare Conference GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company...
GRAIL, Inc. has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference scheduled for September 9. The company's focus on early cancer detection underscores its commitment to improving care outcomes. Interested parties can access live and archived webcasts from the event through GRAIL's investor relations website.
Read more →GRALGRAIL Reports Second Quarter 2025 Financial Results Q2 U.S. Galleri Revenue Grew 21% Year-Over-Year to $34.2 Million Q2 Galleri Tests Sold Grew 29% Year-Over-Year to More Than 45,000 Detailed Results From First 25,000 En
GRAIL, Inc. reported its second quarter 2025 financial results, with significant growth in revenue and test sales. Galleri's U.S. revenue rose 21% year-over-year, totaling $34.2 million, while over 45,000 tests were sold. Despite a notable net loss of $114 million, the company showed improvement in operational metrics and cash position. Positive data from the PATHFINDER 2 study is set for a presentation in October 2025, fueling further optimism regarding Galleri's market potential.
Read more →GRALNot All MCED Tests are Created Equal: The Realities of MCED Test Development and Validation
The article discusses the importance of rigorous clinical validation for multi-cancer early detection (MCED) tests, particularly in the intended use population. It emphasizes that tests should not be introduced into clinical practice without strong evidence of safety and effectiveness. The Galleri test by GRAIL is highlighted as a successful example of validated MCED technology, while cautioning against premature launches of other tests lacking proper validation.
Read more →GRALGRAIL to Present at Canaccord Genuity 45th Annual Growth Conference GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company...
GRAIL, Inc. has announced that its management will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 13. This event highlights GRAIL's commitment to early cancer detection, a critical area in healthcare. The company will provide live and replay webcasts accessible through their investor relations website, ensuring broad access to key information regarding their initiatives. The webcast will be available for at least 30 days post-event.
Read more →GRAL▼ -10.8%on this newsshared move
GRAIL to Announce Second Quarter 2025 Financial Results GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue...
GRAIL, Inc. announced that it will release its financial results for the second quarter of 2025 on August 12, 2025. Following the announcement, the company plans to host a webcast and conference call to discuss the results and business progress. The event is open to all interested parties and available through the company's investor relations website.
Read more →GRAL▲ +15.2%on this news
GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced positive top-line...
GRAIL, Inc. announced positive results from its PATHFINDER 2 study, demonstrating better performance and safety for the Galleri multi-cancer early detection test. The study involved over 25,000 participants and found that adding Galleri to standard cancer screening improved cancer detection rates. The positive predictive value for cancer has significantly increased compared to previous studies, while no serious safety concerns were reported. GRAIL plans to submit these results for FDA approval as part of its premarket application in the first half of 2026.
Read more →GRALGRAIL to Present at Jefferies Global Healthcare Conference 2025 GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company...
GRAIL, Inc. has announced that it will present at the Jefferies Global Healthcare Conference 2025, scheduled for June 4 at 11:40 a.m. ET. The event highlights GRAIL's commitment to early cancer detection, which is central to its mission. Interested parties can access live and archived webcasts of the presentation through the company's investor relations website.
Read more →GRAL▲ +19.2%on this news
GRAIL Reports First Quarter 2025 Financial Results Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Ca
GRAIL, Inc. reported strong financial results for Q1 2025, with U.S. Galleri revenue growing 22% year-over-year to reach $28.7 million. The company also announced positive results from the NHS-Galleri trial, indicating high accuracy of the Galleri test in detecting multiple cancers. Despite these advancements, GRAIL faced a net loss of $106.2 million for the quarter. Their cash position remains robust at $677.9 million, ensuring a runway through 2028.
Read more →GRALGRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with ...
GRAIL, Inc. has announced a partnership with athenahealth to enhance the ordering process for its Galleri multi-cancer early detection test. This collaboration will allow over 160,000 clinicians to seamlessly integrate Galleri orders into their electronic health records. The Galleri test aims to detect cancer earlier by identifying DNA fragments shed by tumors, thereby improving access to critical early screening. However, it is prescribed only for patients at higher risk of cancer, and results require careful interpretation due to potential inaccuracies.
Read more →GRALGRAIL to Announce First Quarter 2025 Financial Results GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue...
GRAIL, Inc. announced that it will release its financial results for the first quarter of 2025 on May 13, 2025. Following the release, a webcast and conference call will be held to discuss the results and the company's business progress. This event is open to all interested parties, highlighting GRAIL's commitment to transparency and investor relations.
Read more →GRAL▲ +12.4%on this news· ran to +41% by day 3
GRAIL to Present New Data on Galleri® and its Methylation Platform at American Association for Cancer Research (AACR) Annual Meeting GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present new data highlighting the ...
GRAIL, Inc. will present new data on its Galleri multi-cancer early detection test and its targeted methylation platform at the AACR Annual Meeting. The company reports real-world evidence demonstrating the test's ability to screen for multiple cancers and accurately predict cancer origins. These findings are based on data from over 100,000 patients, showcasing the test's potential in improving cancer diagnostics.
Read more →GRALGRAIL Partners With Actress Kate Walsh for Generation Possible to Raise Awareness of Multi-Cancer Early Detection Testing GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, has partnered with award-winning...
GRAIL, Inc. has partnered with actress Kate Walsh to launch an educational initiative called Generation Possible, aimed at raising awareness of multi-cancer early detection (MCED) testing. This initiative emphasizes the importance of early cancer screenings, particularly for the 46% of Americans aged 50-75 who are concerned about cancer. Kate Walsh, motivated by her parents' experiences with cancer, advocates for the benefits of MCED testing, which offers new screening options for cancers that currently have no recommended tests. GRAIL aims to educate the public on the potential of MCED testing to transform cancer screening.
Read more →GRAL▼ -14.7%on this newsshared move
GRAIL to Present at TD Cowen 45th Annual Health Care Conference GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company...
GRAIL, Inc. (Nasdaq: GRAL) has announced its participation in the TD Cowen 45th Annual Health Care Conference, which will take place in Boston on March 4. The management will present at 9:10 a.m. ET, promoting the company's mission of early cancer detection. Attendees can access live webcasts and replays through GRAIL's investor relations website, with archives available for 30 days post-event.
Read more →GRAL▼ -9.2%on this news· ran to -23% by day 1shared move
GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results Sold More Than 137,000 Galleri Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits For Two Registratio
GRAIL, Inc. reported strong financial results for the fourth quarter and full year of 2024, achieving a 45% increase in Galleri revenue to $108.6 million. The company ended the year with a cash position of $767 million, which supports its operational runway into 2028. However, net losses increased significantly to $2.0 billion due to impairments related to goodwill and other intangible assets. The company is also positioned for future growth with TRICARE coverage for its Galleri test and ongoing clinical studies aimed at regulatory submissions in 2026.
Read more →GRAL▲ +18.4%on this news· ran to +59% by day 1
GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, and Quest Diagnostics (NYSE: DGX), a...
GRAIL, Inc. has partnered with Quest Diagnostics to enhance accessibility to its Galleri multi-cancer early detection test. Physicians can now order the Galleri test through Quest's digital connectivity system, improving the overall experience for providers and patients alike. This collaboration is designed to maximize patient access to the test by utilizing Quest's nationwide patient access points. The Galleri test aims to identify cancer signals through a simple blood draw, facilitating earlier detection and intervention.
Read more →GRAL▲ +18.4%on this news· ran to +59% by day 1
GRAIL to Announce Fourth Quarter 2024 Financial Results GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue...
GRAIL, Inc. has announced that it will release its financial results for the fourth quarter of 2024 on February 20, 2025. Following the release, the company will hold a webcast and conference call to discuss the results and progress in its business operations. This event is expected to provide valuable insights for investors and stakeholders regarding GRAIL's financial health and strategic direction.
Read more →GRALPatient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported...
GRAIL, Inc. announced the publication of patient-reported outcomes from the PATHFINDER study in Lancet Oncology. The analysis indicated minimal distress related to the Galleri multi-cancer early detection test, with high satisfaction levels reported among participants. Most individuals with a negative signal expressed relief regarding their test results, while those with a cancer signal showed a quick return to baseline distress levels within a year. The findings suggest that such testing could improve patient adherence to future cancer screening protocols.
Read more →GRAL▼ -23.4%on this news
GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company...
GRAIL, Inc. will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th. The event is significant for the company as it aims to showcase its advancements in early cancer detection. Management's presentation is expected to highlight GRAIL's mission and innovations. Investors can access live and archived webcasts from the event on the company's investor relations page.
Read more →GRAL▲ +5.6%on this news· ran to +18% by day 3
GRAIL to Participate in Upcoming Investor Conferences GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company...
GRAIL, Inc. announced its upcoming participation in several investor conferences, highlighting its mission to detect cancer early for effective treatment. The company management will present at these conferences and provide webcasts accessible through their investor relations section. These events are significant as they may improve investor engagement and awareness of GRAIL's efforts in cancer detection.
Read more →GRAL▼ -5.4%on this newsshared move
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient ...
GRAIL, Inc. has announced that the first patient has been tested with its investigational ctDNA assay in the global TROPION-Lung12 Phase 3 study. This study, aimed at assessing adjuvant treatment regimens for patients with Stage I adenocarcinoma non-small cell lung cancer, is sponsored by AstraZeneca. GRAIL's approach allows for blood-only testing, eliminating the need for tumor tissue and simplifying the clinical trial process. The study hopes to demonstrate the potential of GRAIL's assay in better selecting patients for post-surgery treatment.
Read more →GRALGRAIL Reports Third Quarter 2024 Financial Results Galleri Revenue Grew 52% Year-Over-Year to $25.4 Million Commercial Galleri Sales Surpassed 250,000 Tests Since Launch Cash Balance of $853.6 Million Provides Runway Int
GRAIL, Inc. has reported its third-quarter financial results for 2024, achieving a 38% year-over-year revenue increase to $28.7 million. The Galleri multi-cancer early detection test saw a remarkable revenue growth of 52%, reaching $25.4 million, with total sales surpassing 250,000 tests. Despite these positive developments, GRAIL recorded a net loss of $125.7 million, which reflects ongoing financial challenges including significant restructuring costs. Nevertheless, the company maintains a strong cash position of $853.6 million, providing financial stability as it prepares for further clinical studies and regulatory submissions.
Read more →GRALGRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company...
GRAIL, Inc. has announced that its management will be presenting at the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum in New York on November 21. This event aims to highlight innovations in early cancer detection, aligning with GRAIL's mission. In addition, live webcasts of the presentation will be accessible through the company's investor relations website, with an archive available for at least 30 days post-event.
Read more →GRALGRAIL to Announce Third Quarter 2024 Financial Results GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue...
GRAIL, Inc. has announced that it will release its financial results for the third quarter of 2024 on November 12, 2024. Following the release, company management will conduct a webcast and conference call to discuss the results and the progress of the business. Interested parties are invited to access the live event via the company's investor relations website.
Read more →GRALGRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced early results from the ...
GRAIL, Inc. presented early findings from its REFLECTION study at the Early Detection of Cancer Conference, showcasing the effectiveness of the Galleri multi-cancer early detection test among a diverse cohort of veterans. The study indicated a cancer signal detection rate of 1.30%, consistent with prior testing populations, and highlighted that many diagnosed cancers were identified at early stages. The research underscores the potential of the Galleri test to improve early cancer detection in veterans, particularly those with toxic exposures, and aims to address the unmet medical need in cancer screening.
Read more →GRALGRAIL Appoints Sarah Krevans to Board of Directors GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of...
GRAIL, Inc. has appointed Sarah Krevans to its Board of Directors, effective immediately. Krevans, who previously served as president and CEO of Sutter Health, brings extensive experience in healthcare leadership. She will also be a member of several Board Committees, including Audit, Compensation, and Nominating and Governance. CEO Bob Ragusa expresses confidence in Krevans' ability to enhance GRAIL's mission of early cancer detection as the company seeks to establish new standards of care.
Read more →GRALDocument NEWS RELEASE GRAIL Appoints Sarah Krevans to Board of Directors
GRAIL, Inc. has appointed Sarah Krevans to its Board of Directors, effective immediately. Krevans brings extensive experience from her tenure as president and CEO of Sutter Health and has held various leadership roles throughout her career. The board now comprises five directors, four of whom are independent. GRAIL aims to leverage Krevans' expertise to advance its mission of early cancer detection.
Read more →GRALGRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted...
GRAIL, Inc. (Nasdaq: GRAL) recently announced the granting of equity awards in the form of restricted stock units (RSUs) to 55 new non-executive employees. This decision aligns with Nasdaq Listing Rule 5635(c)(4) as part of GRAIL's Inducement Equity Incentive Plan. The RSUs, which amount to 182,223 shares of common stock, will vest over a four-year period, incentivizing the new hires to remain with the company. GRAIL's mission focuses on early cancer detection, highlighting its commitment to advancing healthcare.
Read more →GRALResults of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings...
GRAIL, Inc. announced positive findings from its Galleri multi-cancer early detection test for prostate cancer, which effectively identifies more aggressive cancers. Published data from a study indicated that 93% of the detected cancers were clinically significant, with a high accuracy in predicting cancer signal origin. The study emphasizes that the Galleri test minimizes the risk of overdiagnosing indolent cancers while necessitating prompt evaluation for aggressive diseases when a cancer signal is detected.
Read more →GRAL▲ +5.4%on this news
GRAIL to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company...
GRAIL, Inc. has announced that its management will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024. The company focuses on early cancer detection, emphasizing its commitment to improving patient outcomes. Investors will have access to live and replay webcasts from the conference on GRAIL's investor relations website. The archived webcasts will remain available for at least 30 days after the event.
Read more →GRALGRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update Second Quarter Revenue Grew 43% Year-Over-Year to $32.0 Million Portfolio Prioritization and Corporate Restructure Extends Cash Runway i
GRAIL, Inc. reported its financial results for the second quarter of 2024, showing a 43% increase in revenue year-over-year to $32 million. However, the company also faced a substantial net loss of $1.59 billion, largely due to impairment charges. Following its separation from Illumina, GRAIL is focusing on its Galleri multi-cancer detection test and has initiated several key clinical studies. A corporate restructuring aims to streamline operations and extend the company's cash runway into 2028.
Read more →GRALGRAIL to Announce Second Quarter 2024 Financial Results GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue...
GRAIL, Inc. announced that it will release its financial results for the second quarter of 2024 following the market close on August 13, 2024. The company aims to provide insights into its financial performance and business progress during a subsequent conference call and webcast. Interested parties can access the live event by registering through the company's investor relations website. This announcement aligns with GRAIL's mission to focus on early cancer detection.
Read more →GRAL▼ -14.6%on this news
GRAIL Announces First Participant Enrolled in REACH Study Evaluating Clinical Impact of Galleri® Multi-Cancer Early Detection (MCED) Test in the Medicare Population GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first...
GRAIL, Inc. has announced the enrollment of the first participant in its REACH study, which evaluates the clinical impact of the Galleri multi-cancer early detection test among Medicare beneficiaries. The study, being conducted in partnership with Community Health Network, aims to include a diverse demographic and assess healthcare outcomes in underrepresented populations. Medicare will cover associated costs, signifying a commitment to expand access for at-risk seniors. The findings are expected to enhance understanding of the test's effectiveness in real-world scenarios and potentially improve early cancer detection rates.
Read more →GRAL▲ +5.3%on this news· ran to +31% by day 1shared move
GRAIL Advances the Galleri® Registrational Clinical Trial Program GRAIL, Inc. (NASDAQ: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today provided an update on the...
GRAIL, Inc. has announced significant advancements in its Galleri multi-cancer early detection test through the completion of participant enrollment in the PATHFINDER 2 study and the NHS-Galleri trial. Over 35,000 participants have been enrolled for PATHFINDER 2, which aims to evaluate the test's safety and performance, with results from 25,000 individuals expected in 2025. The NHS-Galleri trial has enrolled over 140,000 participants and is designed to assess the impact of Galleri on reducing late-stage cancer incidence. Both studies will contribute crucial data to support GRAIL's FDA premarket approval application.
Read more →GRAL▼ -6.1%on this news
GRAIL applauds policymakers’ commitment to MCED access
GRAIL has expressed support for the unanimous vote by the House Committee on Ways and Means to advance the 'Nancy Gardner Sewell Medicare Multi-Detection Early Detection Screening Coverage Act.' This legislation aims to ensure that Medicare beneficiaries can access multi-cancer early detection tests once approved by the FDA. However, the bill must still pass through Congress and receive presidential approval to become law.
Read more →GRALGRAIL stands with policymakers and stakeholders for Medicare access framework
GRAIL, alongside 52 advocacy organizations, advocates for timely Medicare access to multi-cancer early detection (MCED) tests. They emphasize the importance of legislative action to prevent delays in access for Medicare beneficiaries, particularly the elderly, who are at higher risk for cancer. The initiative aims to eliminate barriers to innovative cancer screening technologies.
Read more →GRALINFORMATION STATEMENT GRAIL, LLC 1525 O Brien Drive Menlo Park, California 94025 Common Stock (par value $0.001) We are sending you this Information Statement in connection with Illumina, Inc. s partial spin-off of its w
Illumina, Inc. is set to complete a partial spin-off of its subsidiary GRAIL, LLC, transforming it into GRAIL, Inc. The spin-off is mandated by European Commission regulations following the prohibition of Illumina's acquisition of GRAIL. Stockholders of Illumina will receive GRAIL common stock on a pro-rata basis, at a ratio of one GRAIL share for every six Illumina shares held. The distribution will be tax-free for U.S. federal income tax purposes and is expected to take effect on June 24, 2024.
Read more →GRALGRAIL Update on the Accelerated Implementation of Multi-Cancer Early Detection Technology by NHS England
NHS England has reviewed early results from the NHS-Galleri trial, which assesses the Galleri test for early cancer detection. Although the initial findings are promising, NHS England has decided to wait for the final results expected in 2026 before considering a pilot implementation. This cautious approach reflects the need for comprehensive data over multiple screening years.
Read more →GRALApril 2024 Business Update
GRAIL reported a revenue of $26.7 million in Q1 2023, driven by Galleri test sales and partnerships. The company has surpassed 10,000 prescribers and completed over 180,000 tests. Key clinical studies, including NHS-Galleri and PATHFINDER 2, are progressing well, with results expected in the coming years. New partnerships are enhancing the accessibility of Galleri.
Read more →GRALAssessing Accelerated Implementation of Multi-Cancer Early Detection Technology in England to Help Address the Ever-Increasing Burden of Cancer
GRAIL's Galleri test is undergoing the NHS-Galleri trial in England, aiming to detect multiple cancers early. NHS England plans to assess preliminary results for a potential pilot program that could offer the test to one million people. While the trial shows promise, early results may not fully represent long-term outcomes, necessitating careful evaluation before implementation.
Read more →GRALFebruary 2024 Business Update
GRAIL reported a strong business update for February 2024, highlighting a 68% revenue increase in 2023, driven by Galleri test sales and partnerships. The company announced the Galleri-Medicare study, aiming to evaluate the test's clinical impact on Medicare beneficiaries. Additionally, partnerships with BeniComp and Curative Insurance enhance access to Galleri for diverse populations, further solidifying GRAIL's market position in multi-cancer early detection.
Read more →GRALReflections on 2023
In 2023, GRAIL reported significant progress with its Galleri multi-cancer early detection test, achieving over 150,000 tests completed and detecting various aggressive cancers early. The company expanded its partnerships, published pivotal study results, and initiated large-scale clinical trials. GRAIL aims to enhance cancer detection and improve healthcare access, with plans for FDA approval and further product launches in 2024.
Read more →GRALGRAIL Public Comments to FDA Advisory Committee on MCD Tests
GRAIL submitted public comments to the FDA regarding Multi-Cancer Detection (MCD) tests, emphasizing the importance of early cancer detection and the Galleri test's ability to identify signals across multiple cancer types. The company advocates for robust study designs to evaluate MCD tests effectively, aiming to complement existing cancer screening methods and improve public health outcomes. GRAIL's engagement with the FDA aims to accelerate the regulatory process for these innovative tests.
Read more →GRALGRAIL Statement on Divestiture
Illumina announced plans to divest GRAIL in compliance with the European Commission's order, aiming for completion by Q2 2024. GRAIL's CEO highlighted the company's advancements in multi-cancer early detection, including the Galleri test and ongoing clinical studies. Illumina remains committed to ensuring GRAIL's viability during the divestiture process.
Read more →GRALNew Study Confirms Cancer Found in Early Stages More Likely to be Cured
A recent study published in Cancer Epidemiology, Biomarkers & Prevention reveals that cancers diagnosed at early stages have a significantly higher cure rate compared to advanced stages. The research analyzed data from 2.4 million cancer cases, highlighting the importance of early detection and the potential of multi-cancer early detection (MCED) tests. Findings indicate that stage at diagnosis is a critical predictor of long-term outcomes, emphasizing the need for improved screening strategies.
Read more →GRALGRAIL Receives ISO 13485 Certification
GRAIL has successfully obtained ISO 13485 certification from BSI for its Quality Management System at its Menlo Park and Durham sites. This certification confirms that GRAIL adheres to international standards for the development and manufacture of regulated medical products, marking a significant advancement for the company.
Read more →GRALNovember 2023 Business Update
GRAIL reported significant advancements in its cancer detection efforts, with over 125,000 Galleri tests returned and new partnerships enhancing access. The PATHFINDER study results were published, showcasing the test's effectiveness in identifying various cancers. However, GRAIL faces a divestment requirement from Illumina as mandated by the European Commission, which may impact its future operations.
Read more →GRALGRAIL Named on Fortune’s Change the World List
GRAIL has been named on Fortune's 2023 Change the World List for its innovative contributions to cancer detection. The company is recognized for its Galleri multi-cancer early detection test, which identifies signals from more than 50 cancer types. GRAIL's mission focuses on early cancer detection to improve treatment outcomes and reduce mortality rates.
Read more →GRALAn Assault On Cancer Screening Will Not Win The War on Cancer
Recent commentary in JAMA Internal Medicine questions the effectiveness of cancer screenings in extending lifespan. While some experts argue that screenings primarily aim to reduce suffering rather than mortality, others emphasize the need for innovative approaches like multi-cancer early detection (MCED) tests. GRAIL's MCED tests, validated through extensive trials, could significantly enhance early cancer detection and improve patient outcomes.
Read more →GRALJuly 2023 Business Update
GRAIL's Galleri multi-cancer early detection test has shown significant commercial progress, achieving a milestone of 100,000 tests prescribed by over 7,500 providers. The company reported a revenue increase to $22 million in Q2 2023 and is on track to meet its annual revenue guidance. Recent research presented at major conferences highlights the effectiveness of Galleri in detecting cancer early and its implementation in health systems.
Read more →GRALGRAIL Appoints Chairman Bill Rastetter to Chief Executive Officer
Founding CEO Jeff Huber Appointed Vice Chairman of the Board of Directors Ken Drazan Promoted to President MENLO PARK, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced le
Read more →GRALGRAIL Announces Data From Early Research Analyzing its High-Intensity Sequencing Approach
CHICAGO, June 03, 2017 (GLOBE NEWSWIRE) -- GRAIL, Inc., a life sciences company focused on the early detection of cancer, today announced results from a study evaluating a novel high-intensity sequencing approach for detecting tumor signals in the bloodstream. Historically, resea
Read more →GRALGRAIL and Cirina Combine to Create Global Company Focused on Early Detection of Cancer
MENLO PARK, Calif., and HONG KONG, May 31, 2017 (GLOBE NEWSWIRE) -- GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced it has entered into a definitive agreement to combine with Cirina, Ltd., a privately held company
Read more →GRALGRAIL Announces Board of Directors Appointments
MENLO PARK, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced the appointment of José Baselga, M.D., Ph.D., Brook Byers and Kaye Foster to its Board of Directors. The three n
Read more →GRALGRAIL Initiates the STRIVE Study to Advance Development of Blood Tests to Detect Cancer Early
MENLO PARK, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced that it has commenced its second multi-center clinical study, the STRIVE Study, to facilitate the development
Read more →GRALGRAIL Closes Over $900 Million Initial Investment in Series B Financing to Develop Blood Tests to Detect Cancer Early
Financing led by ARCH Venture Partners with the largest investment by Johnson & Johnson Innovation; includes additional strategic industry and venture investors GRAIL plans a second close with institutional investors to bring the total raised in the Series B to over $1 billion
Read more →GRALGRAIL Announces Circulating Cell-free Genome Atlas (CCGA) Study as Foundation for Development of Blood Test to Detect Cancer Early
- GRAIL to Apply High-Intensity Sequencing on an Unprecedented Scale to Build an Atlas of Cancer Biology - - Initial Collaborators Include Guardian Research Network, Mayo Clinic and Hartford HealthCare Cancer Institute - MENLO PARK, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- GRA
Read more →GRALGrail Advisors Announces Record Date for Special Meeting of ETF Shareholders
SAN FRANCISCO, CA--(Marketwire - Apr 15, 2011) - Grail Advisors, LLC today announced that the firm has entered into an agreement to be acquired by Columbia Management Investment Advisers, LLC. The transaction is expected to close in May. Terms have not been disclosed. The Board
Read more →GRALGrail Advisors and RiverPark Capital Fine-Tune Investment Lineup
NEW YORK, NY--(Marketwire - August 20, 2010) - Grail Advisors, an innovator in the development and distribution of actively-managed exchange traded funds (ETFs), and RiverPark Capital, a leading money manager, today announced that they will close two funds, RP Technology ETF (RPQ
Read more →GRALGrail Advisors Forms Strategic Relationship With DoubleLine Capital
SAN FRANCISCO, CA--(Marketwire - June 24, 2010) - Grail Advisors, an innovator in the development and distribution of actively-managed exchange traded funds (ETFs), today announced it has formed a strategic partnership with DoubleLine Capital LP. Grail Advisors has filed registr
Read more →GRALGrail Advisors Adds Western Asset Management to Growing List of Strategic Partners
SAN FRANCISCO, CA--(Marketwire - May 17, 2010) - Grail Advisors, an innovator in the development and distribution of actively-managed exchange traded funds (ETFs), today announced the firm has formed a strategic partnership with Western Asset Management Company. Grail Advisors h
Read more →GRALGrail Advisors Issues White Paper on Exchange-Traded Bond Funds
SAN FRANCISCO, CA--(Marketwire - April 20, 2010) - Grail Advisors, a leader in the development and distribution of actively-managed Exchange Traded Funds (ETFs), today announced the firm has issued a white paper on Fixed Income ETFs and the state of the ETF marketplace. The pape
Read more →GRALGrail Advisors Building out Fixed Income Presence in Actively-Managed ETF Space
SAN FRANCISCO, CA--(Marketwire - October 8, 2009) - Grail Advisors, an innovator in the development and distribution of active-managed exchange traded funds (ETFs), today announced the registration of a new actively-managed fixed-income ETF -- RP Short Duration Bond ETF. New
Read more →GRALGrail Advisors Bringing Fixed Income to Actively-Managed ETF Marketplace
SAN FRANCISCO, CA--(Marketwire - October 5, 2009) - Grail Advisors, an innovator in the development and distribution of active-managed exchange traded funds (ETFs), today announced the registration of two new actively-managed fixed-income ETFs -- Grail McDonnell Intermediate M
Read more →GRALGrail Advisors First to Market Again With Launch of Riverpark ETFs
SAN FRANCISCO, CA--(Marketwire - October 1, 2009) - Grail Advisors, an innovator in the development and distribution of active-managed exchange traded funds (ETFs), today announced that trading of its four new actively-managed ETFs -- RP Growth ETF, RP Focused Large Cap Growth
Read more →GRALGrail Advisors Issues White Paper on Exchange-Traded Funds
SAN FRANCISCO, CA--(Marketwire - August 19, 2009) - Grail Advisors, a leader in the development and distribution of active Exchange Traded Funds (ETFs), today issued a white paper on Exchange-Traded Funds and the state of the ETF The paper -- "Exchange-Traded Funds: A Passive
Read more →GRALGrail Advisors to Launch Industry's First Single Manager ETFs Using Traditional Active Management
SAN FRANCISCO, CA--(Marketwire - June 9, 2009) - Grail Advisors, a leader in the development and distribution of active Exchange Traded Funds (ETFs), today announced the registration of four new actively-managed ETFs -- RP Growth ETF, RP Focused Large Cap Growth ETF, RP Techno
Read more →GRALGrail American Beacon Large Cap Value ETF (GVT) Begins Trading on NYSE
SAN FRANCISCO, CA--(Marketwire - May 4, 2009) - Grail Advisors, an innovator in the development and distribution of actively managed exchange traded funds (ETFs), today announced that trading of the "Grail American Beacon Large Cap Value ETF" has begun on the New York Stock Ex
Read more →GRALGrail Advisors Sets Executive Team for Distribution of Industry's First Actively-Managed Exchange Traded Equity Funds
SAN FRANCISCO, CA--(Marketwire - April 7, 2009) - Grail Advisors LLC, an innovator in the creation and distribution of actively-managed Exchange Traded Funds (ETFs), today announced a number of key executive appointments to lead and manage the company's sales and distribution
Read more →GRALGrail Advisors to Launch First Actively-Managed Exchange Traded Equity Funds
SAN FRANCISCO, CA--(Marketwire - January 15, 2009) - Grail Advisors, an innovator in the development and distribution of active Exchange Traded Funds (ETFs), has filed a registration statement for two new actively managed ETFs, the Grail American Beacon Large Cap Value ETF and
Read more →Competitive Position
How GRAL ranks across every disease it competes inCompetitive Position is a premium feature
See how GRAL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial